Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate

Geriatrics

Volumn 61, Issue 1, 2006, Pages 31-33

  Schneider, Jennifer P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; RISEDRONIC ACID;

ADULT; ARTICLE; BONE DENSITY; BONE SCINTISCANNING; CASE REPORT; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE COURSE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR FRACTURE; FRACTURE NONUNION; HIP RADIOGRAPHY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; PHYSICAL ACTIVITY; STRESS FRACTURE; TREATMENT INDICATION; TREATMENT OUTCOME;

ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DENSITOMETRY, X-RAY; DRUG THERAPY, COMBINATION; FEMALE; FEMORAL FRACTURES; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; OSTEOPOROSIS; TIME FACTORS;

EID: 31144448185     PISSN: 0016867X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 1998; 280(24):2077-82.
2. Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999; 9(5):461-8.
3. Tonino RP, Meunier PJ, Emkey R, et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 2000; 85(9):3109-15.
4. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group. J Clin Encocrinol Metab 2000; 85(11):4118-24.
5. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343(9):604-10.
6. Ravn P, Bidstrup M, Wasnich RD, et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: Four-year results from the early postmenopausal intervention cohort study: A randomized, controlled trial. Ann Intern Med 1999; 131(12):935-42.
7. Bone HG, Greenspan SL, McKeever C, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab 2000; 85(2):720-6.
8. Lindsay R, Cosman F, Lobo RA, et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: A randomized, controlled clinical trial. J Clin Endocrinol Metab 1999; 84(9):3076-81.
9. Mashiba, T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001; 28(5):524-31.
10. Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Does suppression of bone turnover impair mechanical properties by allowing microdamage accumulation? Bone 2000; 27(1):13-20.
11. Boivin G, Meunier PJ. Changes in bone remodeling rate influence the degree of mineralization of bone. Connect Tiss Res 2002; 43(2-3):535-7.
12. Akkus O, Polyakova-Akkus A, Adar F, Schaffler MB. Aging of microstructural compartments in human compact bone. J Bone Miner Res 2003; 18(6):1012-9.
13. Ciarelll TE, Fyhrie DP, Parfitt AM. Effects of vertebral bone fragility and bone formation rate on the mineralization levels of cancellous bone from white females. Bone 2003; 32(3):311-5.
14. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90(3):1294-301.
15. Ott SM. Editorial: Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005; 90(3):1897-99.